HIGHLIGHTS
- who: Brenda C. Edina et al. from the States)The study selection was done based on the predetermined patient, intervention, control, and outcome (PICO) criteria, in which we used T DM as the targeted patient, IDegAsp as intervention, other insulin therapy as the control (insulin glargine, insulin aspart, etc.), and primary outcomes of insulin use, that is the changes in hemoglobin A C (HbA C) value (for efficacy) and hypoglycemia incident rate (for safety). We included studies with several inclusion criteria, including (1) randomized clinical trials, (2) studying a population of T DM at any age, (3 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.